Mr. Chair, there's a review process that involves review teams with a lot of experience. Each review team has about seven to 10 people on it, in a variety of different scientific domains. They look at the preclinical, or the lab and animal data, they look at the clinical trial information, and they have detailed examination of the manufacturing data in separate groups and in areas of expertise, and then all of that comes back together to see if that vaccine will meet the appropriate standards for safety, efficacy and quality, as well as whether the benefits of that vaccine outweigh the potential risk.
In addition to that, there's a group that looks at what we call the “risk management plan”, that's the plan for post-market monitoring of the vaccine. We have teams in Health Canada that also look at all of the assessments of the facilities the vaccines will be manufactured in to make sure that they adhere to good manufacturing practices and standards.
Once all of that comes together, there are [Technical difficulty—Editor] that look at the labelling, the post-market commitments, the terms and conditions on the vaccine and the plans for monitoring, and all of that goes into the authorization. All of that [Technical difficulty—Editor] in the Canadian product monograph, a summary of our review, and all the information that we based the review on then goes up on the website so that it is accessible to all Canadians.